From: Nanotechnology approaches to addressing HER2-positive breast cancer
Nanoparticle | Targeting mechanism | Cancer therapy | Multifunction capability | References |
---|---|---|---|---|
Pluronic-based nanocarrier loaded with iron oxide nanoparticles | Chitosan conjugated/HER2 targeting | Doxorubicin | Iron oxide for MRI imaging, Cy5.5 for imaging, doxorubicin for anticancer therapy | Choi et al. (2015) |
PEGylated phospholipid nanobubble | Herceptin targeting HER2 receptors | None | Can potentially deliver anticancer therapy, has ultrasonography capability for imaging | Jiang et al. (2016) |
Mini-nanodrug, co-ligand poly(beta-L-malic acid) (PMLA) | HER2-mRNA-annealing oligonucleotide | None | Functionalization for drugs, targeting peptides, protective PEG, peptides for destabilizing membranes and dyes for imaging | Ding et al., 2017 |
Novel humanized HER2 antibody | Anti-HER2 antibody | None | Can be used in many targeting applications. Has advantages over traditional antibodies | Cao et al. (2015) |
HER2 aptamer-conjugated gold nanostar | 42-base pair HER2 aptamer for targeting HER2 receptors | Reduction of HER2 receptors due to lysosome degradation | This HER2 aptamer gold nanostar can be used for detection while offering drug delivery | Lee et al. (2015) |
Antibody-conjugated gold–gold sulfide nanoparticle | Anti-HER2 antibody conjugated for targeting HER2 receptors | Photothermal therapy | Simultaneously provides targeting contrast agents for imaging and photothermal therapy | Day et al. (2010) |
Iron oxide nanoparticle | Small exocyclic peptide from the 185HER2/neu monoclonal antibody trastuzumab. conjugated for targeting HER2 receptors | Paclitaxel | None | Mu et al. (2015) |